AbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD
Tweet Send to a Friend
AbbVie (NYSE: ABBV) announced positive results from a Phase 2 study (PCYC-1129) evaluating ibrutinib (IMBRUVICA) in patients with chronic graft-versus-host-disease ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
